Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$133.13 USD
-0.80 (-0.60%)
Updated May 9, 2024 04:00 PM ET
After-Market: $133.08 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Ascendis Pharma A/S [ASND]
Reports for Purchase
Showing records 41 - 60 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
SKYTROFA Unfazed by the Once-Weekly GH Competition; Focus Remains on TC-PTH/HP
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
ENDO 2023: Impressive 52wk Ph3 PaTHway Results for TCPTH/ HP; TC-hGH Update
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-PTH Compassionate Use Program Opened in Germany; Potential EU Approval in Q4
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Focusing in on TC-IL-2â/ã At Oncology RD Day Ahead of ASCO
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A